— Generic drugmaker Sanofi (NASDAQ: SNY) reported net income of EUR 1.77 billion or EUR 1.49 per share for the third quarter, on IFRS basis, down 23.% and 18.6% respectively from last year
— IFRS net sales increased 1.1% year-over-year to EUR 9.5 billion, on a reported basis
— Sanofi Genzyme sales rose 19.5% annually, aided by continued strong uptake of Dupixent
— Vaccine sales decreased 9.8%, reflecting anticipated weighing of flu vaccine supply towards year-end
— Expects business earnings to grow about 5%, on a constant-currency basis and excluding one-off items, in fiscal 2019
— During the quarter, European Commission approved Dupixent for severe chronic rhinosinusitis
— Achieved positive results from advanced-stage study on Dupixent for severe atopic dermatitis in children